Aadi Bioscience Q2 EPS $(0.67) Misses $(0.62) Estimate, Sales $6.20M Beat $6.20M Estimate
Portfolio Pulse from Benzinga Newsdesk
Aadi Bioscience reported Q2 losses of $(0.67) per share, missing the analyst consensus estimate of $(0.62) by 8.06%. However, the company's quarterly sales of $6.20 million beat the estimate by 0.03%, marking an 80.45% increase from the same period last year.
August 09, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Aadi Bioscience's Q2 earnings per share missed estimates, but sales exceeded expectations and showed significant YoY growth.
Aadi Bioscience's Q2 earnings per share missed the analyst consensus, which could negatively impact the stock. However, the company's sales beat estimates and showed a significant year-over-year increase, which could offset the negative impact of the earnings miss.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100